



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/031,180	08/05/2002	Alistair Dixon	A0000096-01-SMH	2579		
7590 10/27/2005			EXAM	INER		
Suzanne M Harvey			HUI, SAN MING R			
Warner Lamber 2800 Plymouth			ART UNIT	PAPER NUMBER		
Ann Arbor, MI		. 1617				
·			DATE MAIL ED. 10/27/2004	DATE MAIL ED. 10/27/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)					
		10/031,180	DIXON ET AL.					
Office Action Summary		Examiner	Art Unit	<u> </u>				
		San-ming Hui	1617					
The MAILING DATE of this	communication app	•		ddress				
Period for Reply			•					
A SHORTENED STATUTORY PE WHICHEVER IS LONGER, FROM - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date - If NO period for reply is specified above, the reliable to reply within the set or extended per Any reply received by the Office later than threatned patent term adjustment. See 37 CFR	A THE MAILING DA e provisions of 37 CFR 1.13 of this communication. naximum statutory period w iod for reply will, by statute, ee months after the mailing	ATE OF THIS COMMUNI (6(a). In no event, however, may a ill apply and will expire SIX (6) MO cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this of BANDONED (35 U.S.C. § 133).	,				
Status								
1) Responsive to communicati	on/s) filed on 10 Au	iquet 2005						
2a) ☐ This action is FINAL .		action is non-final.						
<u> </u>								
,— ,,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims		, , , , , , , , , , , , , , , , , , ,	,					
	is/are pending in th	o application						
	4) Claim(s) 8.10-25,52 and 53 is/are pending in the application.							
5) Claim(s) is/are allowed	4a) Of the above claim(s) is/are withdrawn from consideration.							
	6)⊠ Claim(s) <u> </u>							
8) Claim(s) are subject		election requirement.						
Application Papers		·						
<u> </u>	to by the Evenine							
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119	,							
<u> </u>	a claim for foreign	priority under 25 U.S.C.	\$ 110(a) (d) ar (f)					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	_							
3. Copies of the certified copies of the priority documents have been received in this National Stage								
	application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
		·						
Attachment(s)								
1) Notice of References Cited (PTO-892)		4) Interview	Summary (PTO-413)					
2) D Notice of Draftsperson's Patent Drawing		Paper No(s)/Mail Date	0.450)				
 Information Disclosure Statement(s) (PTO Paper No(s)/Mail Date 8-19-05. 	D-1449 or PTO/SB/08)	5) Motice of I	nformal Patent Application (PTC 	J-152)				

Art Unit: 1617

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 19, 2005 has been entered.

As the specie, *N-cyclopropylmethoxy-3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzmaide*, has been found to be free of the prior art, the search herein has been extended, in this instance, to all species of MEK inhibitor compounds of formula I.

Claims 8, 10-25, and 52-53 are pending.

The outstanding rejections under 35 USC 103(a) are withdrawn in view of the amendments filed August 19, 2005, as the claims are no longer directed to the method of treating chronic pain broadly.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/031,180

Art Unit: 1617

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 8, 10-25, and 52-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 316 630 ('630).

'630 teaches that the active compounds of Formula I, which overlaps on scope of the herein claimed compounds, as cycloxygenase inhibitors and are useful in pharmaceutical composition and methods for treating arthritis and pain (see abstract, page 5, line 1 – page 6, line 52, page 8, lines 40-41 and claims 1-17).

'630 does not expressly teach the herein claimed compounds as useful in a method of treating chronic pain associated with arthritis.

It would have been obvious to one of ordinary skill in the art at the time of invention to employ the herein claimed compounds in the method of treating chronic pain associated with arthritis.

One of ordinary skill in the art would have been motivated to employ the herein claimed compounds in the method of treating chronic pain associated with arthritis since all of the compounds in '630 as known to be useful in treating arthritis. Employing any of the compounds of '630 including the herein claimed compounds would be reasonably expected to be effective in treating arthritis and the pain associated with.

Art Unit: 1617

Response to Arguments

Page 4

Applicant's arguments with respect to claims 8, 10-25, and 52-53 have been considered but are most in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1617